Observed arrival · 2026-10-15
Atlas: regulator-cited nonclinical precedents
An open evidence browser for nonclinical precedents across approved bispecifics, ADCs, oligonucleotides, gene therapies, and cell therapies.
○Open
⊠Login
$Paid
†Ads
✦Pretty
●Pro
◎Niche
◉Human
⚑Risk
ƒJS
- For
- Regulatory toxicologists and drug-development teams
- Worth noticing
- The five boards cover 109 approvals; the site says only 9 of 109 public reviews state how the first human dose was set.
Field notes
Each modality board lists approved products and nonclinical markers such as species used, longest study duration, and whether first-dose rationale was disclosed. Atlas says its corpus covers every approval in those five modalities and links answers to FDA or EMA source pages. The homepage also promotes a free plan checker, while plain-language Ask Atlas remains invite-only beta.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
○OpenPublic substance visible
✦PrettyNotable craft visible
●ProPolished or operationally mature
◎NicheUnusually specific use
One card from the complete issue